File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study

TitleEffect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study
Authors
Issue Date2000
PublisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.com
Citation
Journal Of Rheumatology, 2000, v. 27 n. 7, p. 1759-1765 How to Cite?
AbstractObjective. To study the effect of chronic steroid therapy on bone mineral density (BMD) in premenopausal women with normal menstrual cycles and its treatment. Methods. A double blind placebo controlled study to evaluate 81 premenopausal women with systemic lupus erythematosus (SLE), aged 31.1 ± 6 years, taking chronic steroid therapy, with a mean cumulative prednisone dose of 28 ± 16.2 g. They were randomly allocated to 3 groups: Group 1:0.5 μg calcitriol and 1200 mg calcium daily; Group 2:1200 mg calcium and placebo calcitriol; and Group 3: both placebo calcitriol and placebo calcium. Results. Baseline T score at the lumbar spine was > -1 in 56.8% and < -2.5 in 3.7% of the patients. At the end of 2 years, patients in the calcitriol group exhibited a significant increase of 2.1 ± 2.4% in BMD at the lumbar spine compared to baseline value (p < 0.05). This change was not significantly different from the respective change in either calcium or placebo group (0.4 ± 2.9% and 0.3 ± 3.5%, respectively). No significant changes were observed in any treatment group in BMD at the hip or radius. Alkaline phosphatase increased both in the placebo (baseline: 57.5 ± 17.5 IU/l; year 2:60.9 ± 15.3 IU/l) and the calcium group (baseline: 53.6 ± 16.6 IU/l; year 2:59.0 ± 22.8 IU/l), but this increase reached statistical significance only in the calcium group, while the same variable remained stable in the calcitriol group (baseline: 53.9 ±14.1 IU/l; year 2:54.6 ± 12.3 IU/l). Conclusion. Premenopausal women with SLE taking prolonged steroid therapy had lower BMD but showed no significant bone loss over the 2 year study period. The beneficial effect of calcitriol treatment in these premenopausal women was small, at least when it was instituted late in the course of steroid therapy.
Persistent Identifierhttp://hdl.handle.net/10722/162395
ISSN
2015 Impact Factor: 3.236
2015 SCImago Journal Rankings: 1.225
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLambrinoudaki, Ien_US
dc.contributor.authorChan, DTMen_US
dc.contributor.authorLau, CSen_US
dc.contributor.authorWong, RWSen_US
dc.contributor.authorYeung, SSCen_US
dc.contributor.authorKung, AWCen_US
dc.date.accessioned2012-09-05T05:19:34Z-
dc.date.available2012-09-05T05:19:34Z-
dc.date.issued2000en_US
dc.identifier.citationJournal Of Rheumatology, 2000, v. 27 n. 7, p. 1759-1765en_US
dc.identifier.issn0315-162Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/162395-
dc.description.abstractObjective. To study the effect of chronic steroid therapy on bone mineral density (BMD) in premenopausal women with normal menstrual cycles and its treatment. Methods. A double blind placebo controlled study to evaluate 81 premenopausal women with systemic lupus erythematosus (SLE), aged 31.1 ± 6 years, taking chronic steroid therapy, with a mean cumulative prednisone dose of 28 ± 16.2 g. They were randomly allocated to 3 groups: Group 1:0.5 μg calcitriol and 1200 mg calcium daily; Group 2:1200 mg calcium and placebo calcitriol; and Group 3: both placebo calcitriol and placebo calcium. Results. Baseline T score at the lumbar spine was > -1 in 56.8% and < -2.5 in 3.7% of the patients. At the end of 2 years, patients in the calcitriol group exhibited a significant increase of 2.1 ± 2.4% in BMD at the lumbar spine compared to baseline value (p < 0.05). This change was not significantly different from the respective change in either calcium or placebo group (0.4 ± 2.9% and 0.3 ± 3.5%, respectively). No significant changes were observed in any treatment group in BMD at the hip or radius. Alkaline phosphatase increased both in the placebo (baseline: 57.5 ± 17.5 IU/l; year 2:60.9 ± 15.3 IU/l) and the calcium group (baseline: 53.6 ± 16.6 IU/l; year 2:59.0 ± 22.8 IU/l), but this increase reached statistical significance only in the calcium group, while the same variable remained stable in the calcitriol group (baseline: 53.9 ±14.1 IU/l; year 2:54.6 ± 12.3 IU/l). Conclusion. Premenopausal women with SLE taking prolonged steroid therapy had lower BMD but showed no significant bone loss over the 2 year study period. The beneficial effect of calcitriol treatment in these premenopausal women was small, at least when it was instituted late in the course of steroid therapy.en_US
dc.languageengen_US
dc.publisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.comen_US
dc.relation.ispartofJournal of Rheumatologyen_US
dc.subject.meshAdrenal Cortex Hormones - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshAdulten_US
dc.subject.meshAge Factorsen_US
dc.subject.meshBone Density - Drug Effects - Physiologyen_US
dc.subject.meshCalcitriol - Administration & Dosageen_US
dc.subject.meshCalcium - Blooden_US
dc.subject.meshChinaen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLupus Erythematosus, Systemic - Drug Therapyen_US
dc.subject.meshOsteoporosis - Chemically Induced - Drug Therapy - Physiopathologyen_US
dc.subject.meshPremenopause - Drug Effects - Metabolismen_US
dc.subject.meshTime Factorsen_US
dc.titleEffect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled studyen_US
dc.typeArticleen_US
dc.identifier.emailChan, DTM:dtmchan@hku.hken_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.emailKung, AWC:awckung@hku.hken_US
dc.identifier.authorityChan, DTM=rp00394en_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.identifier.authorityKung, AWC=rp00368en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid10914864en_US
dc.identifier.scopuseid_2-s2.0-0033909737en_US
dc.identifier.hkuros69985-
dc.identifier.hkuros51250-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033909737&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume27en_US
dc.identifier.issue7en_US
dc.identifier.spage1759en_US
dc.identifier.epage1765en_US
dc.identifier.isiWOS:000088007600032-
dc.publisher.placeCanadaen_US
dc.identifier.scopusauthoridLambrinoudaki, I=6601969370en_US
dc.identifier.scopusauthoridChan, DTM=7402687700en_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US
dc.identifier.scopusauthoridWong, RWS=34875928200en_US
dc.identifier.scopusauthoridYeung, SSC=7102767673en_US
dc.identifier.scopusauthoridKung, AWC=7102322339en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats